March 21, 2016 at 5:41 pm #91945
Thanks Gavin – that’s all great infoMarch 19, 2016 at 1:13 pm #91941gavinModerator
Welcome to the site. Here is another page with some links on Yeliva for you. Hope that they are of use and interest to you and I look forward to hearing more from you.
GavinMarch 18, 2016 at 3:16 am #91944marionsModerator
A bit more, Mike….. Angiogenesis plays a critical role in the growth and spread of cancer. A blood supply is necessary for tumors to grow beyond a few millimeters in size. Tumors can cause this blood supply to form by giving off chemical signals that stimulate angiogenesis. Tumors can also stimulate nearby normal cells to produce angiogenesis signaling molecules. The resulting new blood vessels “feed” growing tumors with oxygen and nutrients, allowing the cancer cells to invade nearby tissue, to move throughout the body, and to form new colonies of cancer cells, called metastases.
Because tumors cannot grow beyond a certain size or spread without a blood supply, scientists are trying to find ways to block tumor angiogenesis. They are studying natural and synthetic angiogenesis inhibitors, also called antiangiogenic agents, with the idea that these molecules will prevent or slow the growth of cancer.
MarionMarch 18, 2016 at 3:00 am #91943
Thanks so much Marion:
Another article out yesterday. Was Mayo the Phase I? Interesting that it was ‘non-clinical’…
I understood that it was an inhibitor – but some hope in the this statement
“The Mayo researchers, along with Dr. Smith and others, concluded that Yeliva’s targeting of SK2 in the affected cells inhibited cancer proliferation and induced apoptosis – or self-destruction – in the cholangiocarcinoma cells.”
thx! Mike BMarch 18, 2016 at 12:48 am #91942marionsModerator
mikeb…..hello and welcome to our group. I don’t think they set a date for a phase II study as of yet, but it will take some time i.e. months or more.
As far as I understand it, SK2, is an angiogenesis inhibitor, which inhibits the growth of blood vessels. It does not necessarily kill tumors but instead may prevent tumors from growing. It is not a targeted agent and does not require molecular testing.
MarionMarch 17, 2016 at 11:15 pm #12295
I recently saw this press release for YELIVA – ABC294640 – which is focused on Cholangiocarcinoma.
Does anyone know if/when a Trial will take place?
It looks like they have tried initial trial for Lymphoma. Does anyone know any feedback on this trial?
It seems focused on Sphingosine kinase-2 (SK2) inhibitor. I’m not sure if this is important inhibitor in all Cholangiocarcinoma cases, or if only in sub-set with specific markers?
Thanks to anyone with info mb
- You must be logged in to reply to this topic.